GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Helix Introduces Clinico-Genomic Datasets for Cardiovascular, Metabolic, Immunology, and Inflammation Disorders

NextEdge Admin

08 Jun 2024

2 min 27 sec

Cardiovascular,Metabolic,Inflammation Disorders

Helix, a prominent population genomics company, is unveiling clinico-genomic datasets aimed at empowering life science firms in advancing precision medicine drug discovery and development. These datasets, meticulously constructed through Helix's extensive collaborations with health systems, encompass comprehensive longitudinal clinical and genomic records spanning diverse therapeutic domains, including Cardiovascular, Immunology & Inflammation, and Metabolic conditions.

Hylton Kalvaria, Chief Commercial Officer of Helix, highlights the significance of these resources, emphasizing their potential for elucidating genetic determinants of disease progression and clinical outcomes, as well as for validating therapeutic candidates. Moreover, organizations can swiftly pinpoint targeted patient cohorts based on specific genetic and phenotypic criteria, enhancing the efficiency of discovery and clinical development endeavors.

Helix's precision cohorts amalgamate longitudinal clinical data with the company's proprietary Exome+® sequencing data from over 125,000 consented patients across the US, with regular data updates. Partners gain access to structured Electronic Health Record (EHR) fields, encompassing clinical diagnoses, procedures, lab results, and prescriptions. For instance, the newly introduced Cardiometabolic cohort comprises over 50,000 patients with significant Cardiovascular Disease diagnoses, alongside vital patient demographics and key lab metrics like triglycerides and cholesterol, all intricately linked to exome sequencing data covering pertinent Cardiovascular genes.

James Lu, M.D., Ph.D., CEO and co-founder of Helix, underscores the transformative potential of clinico-genomic data in driving the development of targeted therapeutics with enhanced safety and efficacy profiles. Leveraging real-world data and genomics, precision medicine holds the promise of revolutionizing drug development, ushering in an era of personalized treatment paradigms.